Teva Pharmaceutical Industries Q1 Earnings Call Highlights

3 weeks ago 15

MarketBeat

Sat, May 2, 2026 astatine 9:29 AM CDT 7 min read

Teva Pharmaceutical Industries logo

Key Points

Teva reported Q1 gross of $4.0 billion (‑1% y/y) with adjusted EBITDA up 2% to $1.1 billion and non‑GAAP EPS of $0.53, portion its innovative portfolio grew 41% led by Austedo ($578M, +41%), UZEDY (+62%) and AJOVY (+35%).
Teva announced the planned acquisition of Amylyx to adhd ecopipam for Tourette syndrome for an upfront $700 million positive up to $200M successful milestones, expects the woody to adjacent precocious Q2/early Q3, sees ~80% gross borderline if launched successful 2027, and expects the plus to beryllium accretive to non‑GAAP EPS starting successful 2028 (with ~$75M incremental 2026 operating costs and the $700M treated arsenic IP R&D).
Management reiterated its 2027 targets — mid‑single‑digit gross growth, ~30% non‑GAAP operating income, nett debt/EBITDA <2 and 80% cash‑to‑earnings — and said the committee has instructed readying for a imaginable share‑repurchase programme taxable to approval.
Interested successful Teva Pharmaceutical Industries Ltd.? Here are 5 stocks we similar better.

MarketBeat Week successful Review – 02/03 - 02/07

Teva Pharmaceutical Industries (NYSE:TEVA) reported first-quarter 2026 results that absorption said reflected continued momentum successful its innovative portfolio, portion besides outlining the company’s archetypal acquisition nether its “Pivot to Growth” strategy: the planned acquisition of Amylyx and its Tourette syndrome campaigner ecopipam.

Q1 results driven by innovative maturation

President and CEO Richard Francis said Teva had a “good commencement to the year,” led by Austedo, UZEDY, and AJOVY. Teva reported gross of $4.0 billion, down 1% year-over-year, portion adjusted EBITDA roseate 2% to $1.1 billion. Non-GAAP EPS accrued to $0.53 from $0.52, and escaped currency travel accrued to astir $200 cardinal (with CFO Eli Kalif aboriginal citing $188 cardinal for the quarter).

→ Corning Beats Q1 Estimates but Drops 9% connected Guidance Miss

Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now

Francis said gross was “down 1% oregon up 7%, excluding some the Japan divestment and excluding generic Revlimid,” adding that Teva was “able to mitigate the alteration successful generic Revlimid revenues besides arsenic planned.”

Kalif noted Teva’s Q1 2025 results included “approximately $75 cardinal gross publication from the Japan concern venture,” which was divested March 31, 2025, and besides referenced the prior-year publication from generic Revlimid.